ArticleJournal of clinical & experimental ophthalmology2013
Significance of Anti-retinal Autoantibodies in Cancer-associated Retinopathy with Gynecological Cancers.
Article in Journal of clinical & experimental ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Diagnosis and treatment of autoimmune retinopathy: review of current approaches.International ophthalmology · 2025Review
- Rapidly progressive central retinal pigmented epithelium atrophy after Ivospemin (SBP-101) treatment for pancreatic adenocarcinoma.American journal of ophthalmology case reports · 2024Article
- Cancer-associated retinopathy secondary to gallbladder carcinoma.GMS ophthalmology cases · 2024Article
- Current Techniques to Accurately Measure Anti-retinal Autoantibodies.Expert review of ophthalmology · 2020Article
- Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy.Clinical immunology (Orlando, Fla.) · 2020Article
- Beneath the Retinal Pigment Epithelium: Histopathologic Findings in Metastatic Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.Ocular oncology and pathology · 2018Article
- Are Anti-Retinal Autoantibodies a Cause or a Consequence of Retinal Degeneration in Autoimmune Retinopathies?Frontiers in immunology · 2018Review
- Recovery of outer retinal laminations on optical coherence tomography after treatment of cancer associated retinopathy.American journal of ophthalmology case reports · 2017Article
- Acute progressive paravascular placoid neuroretinopathy with negative-type electroretinography in paraneoplastic retinopathy.Documenta ophthalmologica. Advances in ophthalmology · 2017Article
- Impact of Autoantibodies against Glycolytic Enzymes on Pathogenicity of Autoimmune Retinopathy and Other Autoimmune Disorders.Frontiers in immunology · 2017Review
- GCAP1, Rab6, and HSP27: Novel Autoantibody Targets in Cancer-Associated Retinopathy and Autoimmune Retinopathy.Translational vision science & technology · 2016Article
- Latest updates on antiretinal autoantibodies associated with vision loss and breast cancer.Investigative ophthalmology & visual science · 2015Article
- Paraneoplastic neurological complications of breast cancer.Experimental hematology & oncology · 2015Review
- The enigma of autoimmune retinopathy.International ophthalmology clinics · 2015Review
- Prevalence of anti-retinal autoantibodies in different stages of Age-related macular degeneration.BMC ophthalmology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe presence of autoantibodies (AAbs) is the primary serological indicator of autoimmunity. Cancer-associated retinopathy (CAR) is associated with AAbs and different types of cancer. The goal of the study was to examine the profile of serum autoantibodies in women with gynecological cancers with and without paraneoplastic visual manifestation.
methodsRetrospective studies of a cohort of 46 women with symptoms of CAR and gynecological tumors, including endometrial, cervical, ovarian, and fallopian tubes, 111 women with similar tumors without symptoms of CAR, and 60 age-matched healthy controls. Presence of serum AAbs and the identity of targeted antigens were performed by western blotting and their significance was evaluated using an Fisher's exact test.
resultsThe patients with gynecological CAR had the highest proportion of seropositivity (80%), followed by patients with gynecological cancers without CAR (61%) and healthy controls (58%). Differences in recognition frequencies were found for 17 antigens and 5 retinal antigens were frequently targeted: enolase, aldolase C, carbonic anhydrase II, recoverin and GAPDH. The occurrence of anti-glycolytic enzymes was 2-3 times more frequent in CAR and cancer patients than healthy controls. Anti-recoverin AAbs were prevalent in endometrial CAR. Anti-CAII antibodies were not significantly different between groups of women. In this cohort, cancer was diagnosed before the onset of retinopathy with latency from 2 months to 30 years. The discovery of the ovarian and endometrial cancers and manifestation of visual problems often coincided but Fallopian tube carcinoma was found after visual onset.
conclusionNew retinal targets were identified for gynecological CAR. Each gynecological-CAR has its own autoantibody profile different from non-CAR profile, implying that a complex autoantibody signature may be more predictable for diagnosis than a singular AAb. Specific anti-retinal AAbs were most prevalent in women with CAR but their profiles were not fully distinguished from cancer controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.